MedTrace Logo

Efficacy of a Low-Molecular-Weight Heparin (Bemiparin) in the Treatment of Chronic Foot Ulcers in Diabetic Patients

NCT00399425 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2006-11-14

No results posted yet for this study

Summary

To assess the efficacy of bemiparin (low molecular weight heparin) for 3 months in the treatment of chronic foot ulcers in diabetic patients.

Conditions

  • Foot Ulcer, Diabetic
  • Diabetic Angiopathies

Interventions

DRUG

bemiparin (low molecular weight heparin)

Sponsors & Collaborators

  • Carlos III Health Institute

    collaborator OTHER_GOV

  • Rovi Pharmaceuticals Laboratories

    collaborator INDUSTRY

  • Spanish National Health System

    lead OTHER

Principal Investigators

  • Manuel Rullan, MD · Primary health care of Mallorca. Ibsalut.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-06-30
Completion
2004-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00399425 on ClinicalTrials.gov